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Abstract
In recent years, the positron emitter scandium-44 moved into the focus of research pro-
viding favorable nuclide properties for an application in nuclear medicine. Radiolabeling 
of PSMA-617 with scandium-44 as diagnostic match for [177Lu]Lu-PSMA-617 instead 
of gallium-68 would enable pre-therapeutic dosimetry in clinical setting. Due to the 
chemical similarities of scandium and lutetium, the in vitro and in vivo characteristics of 
[177Lu]Lu-PSMA-617 are more similar to [44Sc]Sc-PSMA-617 than to the 68Ga-compounds 
[68Ga]Ga-PSMA-617 or [68Ga]Ga-PSMA-11. [44Sc]Sc-PSMA-617 showed its potential in 
a clinical setting as a PET imaging agent of prostate cancer providing several advan-
tages over gallium-68 labeled tracers. The longer half-life of the nuclide would allow, 
for example, an optimized patient management and treatment, long-term or late time 
point imaging as well as transportation to more distant PET centers. However, espe-
cially clinical applications like individual dosimetry or intraoperative applications are 
still under investigation.
Keywords: scandium-44, PSMA-617, dosimetry, theranostic, castrate-resistant prostate 
cancer
1. Introduction
Prostate carcinoma is the fourth most common cancer in both sexes combined, the second most 
common cancer in men, and with an estimated 307,000 deaths in 2012, it is the fifth leading 
cause of death from cancer in men [1]. While prognosis of prostate carcinoma is good at an early 
stage, the 5-year survival of patients in advanced stages decreases to 31% [2, 3]. Consequently, 
a number of studies were conducted developing new strategies against the disease.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
As the prostate-specific membrane antigen (PSMA) is overexpressed on prostate carcinoma 
and the neovasculature of most of the solid tumors but not of normal tissue, it is an attractive 
target for imaging and therapy [4]. Consequently, the development and the evaluation of 
small ligands targeting PSMA are the objectives of various studies.
With the introduction of PSMA-617, a further development of PSMA-11, a highly potent ther-
anostic agent found its way into clinical routine where it is used as [68Ga]Ga-PSMA-617 for PET 
and as [177Lu]Lu-PSMA-617 for therapy of metastatic castrate-resistant prostate cancer (mCRPC). 
In the last few years, several studies proved the therapeutic efficacy of [177Lu]Lu-PSMA-617 
in mCRPC patients [2, 3, 5]. Although [177Lu]Lu-PSMA-617 exhibited a favorable safety 
profile in mCRPC patients [2, 3, 5–9], adverse effects were due to physiologic expression of 
PSMA in small intestine, proximal renal tubules and salivary glands are observable [2, 10, 11]. 
Correspondingly, organs at risk are kidneys as well as salivary and lacrimal glands. First experi-
ences showed that pre-therapeutic dosimetry might support pre-selection of patients as well as 
improvement of individualized therapy planning [7, 9, 12–15]. In this context, pre-therapeutic 
estimation of dose delivered to PSMA expressing tissue as well as whole body would be useful 
to predict therapeutic effect of a certain administered therapeutic activity and facilitate indi-
vidual dose adjustment [16]. For this purpose, [177Lu]Lu-PSMA-617 planar ± SPECT imaging, 
employing small amounts of tracer, or [68Ga]Ga-PSMA-617 PET were considered [10–14, 17–19] 
but both tracers have disadvantages and limitations for dosimetry in a clinical setting.
Current studies on radiolabeling PSMA-617 with the positron emitter scandium-44 demon-
strated its similar in vitro and in vivo properties compared with [177Lu]Lu-PSMA-617 [20, 21]. 
As it is combining the similar pharmacokinetics to [177Lu]Lu-PSMA-617 with more appropri-
ate nuclide characteristics than [68Ga]Ga-PSMA-617, it is assumed to improve pre-therapeutic 
dosimetry [20, 21].
2. Part I: Radiochemistry
Currently, [68Ga]Ga-PSMA-11 is the most frequently used PET tracer, targeting the prostate-
specific membrane antigen, worldwide [22, 23]. Gallium-68 has for PET imaging appropriate 
decay properties; nevertheless, its disadvantages limit its application.
Its high positron energy compared to fluorine-18 (cf. Table 1) leads to images tending to be 
noisier while its short physical half-life only covers imaging periods of a few hours. Moreover, 
the differences in coordination chemistry between gallium-68 and lutetium-177 lead to devia-
tions in pharmacokinetics [20]. As a consequence, gallium-68 is not the nuclide of choice for 
late time imaging, extended dosimetric evaluations as well as intraoperative applications 
several hours post-injection (p.i.).
From this point of view, scandium-44 is a genuine alternative to gallium-68 and is in the focus 
of current research [20, 25–30].
Scandium-44 (β+ = 94%,  E ~β = 0.632 MeV) has a physical half-life of 3.97 h and can be produced on two different ways, via 44Ti/44Sc-generator or cyclotron [30–36]. Another potential advan-
tage of scandium(III) in nuclear medicine is its radioisotope scandium-47 (β−, primary �-ray of 
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159 keV and t½ = 3.3 d) which is suitable for therapeutical application. Constituting a matched 
pair of radioisotopes real Sc-labeled theranostic radiopharmaceuticals are applicable [28, 31, 
37–40].
Scandium-44 can be quantitatively detected via its 511 keV emission. High radioactivities of 
scandium-44 can be measured in a dose calibrator applying the 18F-setting. But due to differ-
ent radionuclide characteristics, a multiplication factor has to be used, which is depending on 
the dose calibrator.
Since the 1980s, several radiolabeling studies with scandium radionuclides have been pub-
lished [20, 21, 25, 28, 38, 41–44]. Chemically, scandium is similar to Y3+ and lanthanides. 
However, the ionic radius of Sc3+ is smaller than that of lanthanides for the coordination num-
ber 6 while at the same time, it is larger than any trivalent 3d transition metal cation. The most 
common coordination number of Sc3+ is six; nevertheless, examples for coordination numbers 
between three and nine exist [45, 46].
In vivo stability of a radiopharmaceutical is a crucial factor for clinical application; macro-
cyclic ligands are the ligands of choice forming thermodynamically and kinetically stable 
complexes with trivalent hard metal cations. Chemical and, at the end, biological behavior of 
the complex and consequently of the radiopharmaceutical depend on structural factors, for 
example, rigidity, cavity size and nature and number of the donor atoms chelating the metal 
cation [47]. Due to the similarity between Sc3+ and Ga3+, Y3+ or trivalent lanthanides, DOTA, 
a common ligand in nuclear medicine, was evaluated with regard of its usability [48]. The 
study revealed that the stability constant of [Sc-DOTA] is comparable with those for Y3+ or the 
heaviest lanthanides and higher than those for In3+ and Ga3+ as well as the eight-coordination 
geometry of the complex in solution [48].
Together with its four times longer half-life than gallium-68 and its coordination chemistry 
similar to lutetium-177, scandium-44 enables longer imaging periods covering up to 24 h post 
injection as well as improved pre-therapeutic dosimetry.
2.1. Production of scandium-44
Scandium-44 can be produced via 44Ti/44Sc-generator [30, 31, 40]. Despite the advantages of 
the radionuclide generator system prevents the availability of titanium-44 the production 
Positron emitter Half-life  E ~β Eβ, max
(MeV)
68Ga 67.71 min 0.829 1.899
44Sc 3.97 h 0.632 1.474
15O 2.04 min 0.735 1.732
18F 109.77 min 0.250 0.634
Table 1. Comparison of mean ( E ~β) and maximum (Eβ, max) positron energies of scandium-44 with gallium-68, fluorine-18 and oxygen-15 [24].
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of this generator. Titanium-44 with its half-life of 60 years is only producible with limited 
yields and at high costs by a small number of facilities [49]. Accordingly, accessibility of the 
daughter scandium-44 by cyclotron production is an alternative as it provides scandium-44 in 
sufficiently high yields with radionuclidic purities >99% avoiding the problem of 44Ti-waste 
management.
2.1.1. Cyclotron production
Growing interest in scandium-44 as alternative to gallium-68 predicated research for pro-
duction routes providing scandium-44 in the GBq range. Recent intermediate cyclotrons 
allow an economic production of the radionuclide utilizing p, d or α-particle-induced reac-
tions (cf. Table 2) [26, 27, 33, 50–57]. The isomer scandium-44m (T1/2 = 58 h) has also nuclide characteristics, which can be useful in nuclear medicine [26, 43].
Recently, the accessibility of scandium-44 via proton irradiation of natural calcium targets 
was described [53] as well as the employment of enriched calcium targets optimizing radio-
nuclidic purity of the radionuclide produced [52].
Similar experiments performed by bombarding natural calcium targets with protons were 
reported [53, 55], yielding more than 650 MBq scandium-44 with 95.8% radionuclidic purity 
[53]. As this method leads to co-production of long-living radionuclidic impurities accounting 
for unnecessary doses for the patient its usability is limited. To obtain scandium-44 of higher 
radionuclidic purity enriched [44Ca]CaCO3 target material was found to be optimal [59]. This study also confirmed an optimal ratio of scandium-44m to scandium-44 by irradiating the 
targets with 9 MeV protons and the possibility to achieve yields in the GBq range utilizing 
this method [59]. Further refinement leads to reproducible production of GBq-activities of 
scandium-44 at a cyclotron in excellent quality [56]. As a result of all these investigations 
towards scandium-44 production, the basis for the introduction of scandium-44 into clinical 
routine for PET imaging may have been created.
Nuclide production via cyclotron is in need for an efficient separation strategy of the pro-
duced radionuclide from the target material. This is necessary to remove bulk metal, which 
disturbs eventual radiolabeling of PET tracers, to reduce the volume and to recover target 
material. For this purpose, different methods such as filtration [53] or ion exchange employ-
ing chelating resins were investigated [26, 55, 56, 59].
Reaction Q (MeV) E
th
 (MeV)
p 44Ca(p,n)44Sc −4.43 4.53
d 44Ca(d,2n)44Sc −6.65 6.96
44Ca(d,n)44Sc 0.0 0.0
α 44Ca(α,3np)44Sc −32.73 35.71
43Ca(α,2np)44Sc −21.59 23.61
42Ca(α,np)44Sc −13.67 14.97
Table 2. Nuclear reaction data for the formation of scandium-44 [58].
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2.1.2. The 44Ti/44Sc-generator
Radionuclide generators are an alternative production route to reactors and cyclotron. They 
exploit radiochemical equilibria (transient or secular) between mother and daughter isotope. 
This means that the mother isotope has a half-life much greater than or approximately equal 
to 10 times longer than the half-life of the daughter usable for imaging. As mother and daugh-
ter are isotopes of different elements, they are present in different chemical forms and can be 
relatively easily separated chemically.
Beside the 99Mo/99mTc-generator, which is still the working horse in nuclear medicine, the 
relevance of the 68Ge/68Ga-generator continues to increase with recent developments of new 
potent 68Ga-radiopharmaceuticals for PET imaging. Apart from the cyclotron, scandium-44 
can also be produced via 44Ti/44Sc-generator system. Just like the 68Ge/68Ga-generator, there is 
a secular equilibrium between the long-living mother and the short-living daughter nuclide. 
Titanium-44 decays via electron capture (t1/2 = 59 ± 2 a) [60] into the ground state of scan-dium-44 which transforms to the stable calcium isotope calcium-44 emitting a positron.
First studies on the design of a 44Ti/44Sc-generator were conducted in the 1960ies and 70ies 
excluding pharmaceutical aspects [32, 35, 61, 62]. A first 185 MBq 44Ti/44Sc-generator designed 
for radiopharmaceutical use was described in the last decade [31] as well as a suitable post-
processing [40]. An initial preclinical proof of concept study could show that scandium-44 is 
able to radiolabel a clinical relevant precursor (DOTA-TOC) leading to a stable radiophar-
maceutical in good yields as well as the suitability of the generator and post-processing for 
this purpose [38]. Furthermore, a first clinical application of [44Sc]Sc-DOTA-TOC, radiolabeled 
with generator-derived scandium-44, was conducted to proof the high potential of the radio-
nuclide for PET imaging [30].
First challenge in the development of the 44Ti/44Sc-generator is the high-yield production of 
titantium-44 via accelerated particles. Up to now, all attempts building a 44Ti/44Sc-generator 
described in the literature use the 45Sc(p,2n)44Ti-process, although cyclotrons of high posi-
tron flux are necessary, to obtain titanium-44 in relatively low radioactivity yields [31, 32, 35, 
61–63]. Before titanium-44 can be used separation from the target material and subsequent 
purification from residual metallic contaminants is mandatory.
Generally, for the design of a radionuclide generator, several critical radiochemical parameters 
have to be considered, such as separation strategy, stability of the generator and type of eluate. 
In context with the 44Ti/44Sc-generator, this means a separation strategy is needed which pro-
vides high 44Sc-elution yields combined with low 44Ti-breakthrough employing an eluate which 
is suitable for subsequent radiolabeling in terms of pH, volume and purity. Additionally, this 
separation strategy should guarantee high long-term stability of the generator. This is of particu-
lar importance for the 44Ti/44Sc-generator compared for example to the 99Mo/99mTc- or 68Ge/68Ga-
generators as usage for many years due to the long physical half-life of titanium-44 is possible.
The 44Ti/44Sc-generator system developed by Filosofov et al. uses the properties of ScIII in 
oxalic as well as hydrochloric acid as basis of an anion-exchange separation strategy [31]. 
This concept leads to 44Sc elution yields of 180 MBq in 20 ml 0.005 M H2C2O4/0.07 M HCl accompanied by a 44Ti breakthrough of 90 Bq representing a separation factor of 2 × 106 [31]. 
Long-term stability of the generator is ensured by a reverse elution mode which is needed to 
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Figure 1. Putative structure of [44Sc]Sc-PSMA-617.
provide high retention of titanium-44 on the column [31]. This concept leads to a generator 
design providing scandium-44 in stable yields without significant 44Ti-breakthrough since 
approximate 10 years.
As volume, pH and eluent composition of the 180 MBq 44Ti/44Sc generator are not suitable 
for subsequent radiolabeling, for example, peptides for clinical application, an efficient post-
processing strategy in analogy to the post-processing approach of 68Ge/68Ga generators was 
developed [40, 64, 65]. This post-processing includes reduction of the volume of 44Sc solu-
tion, optimization of pH for subsequent radiolabeling as well as further purification from 
metal contaminants disturbing the complex formation by utilizing a cation exchange column. 
Finally, ~ 90% of chemically and radiochemically highly pure scandium-44 can be recovered 
in 3 ml 0.25 M ammonium acetate (pH = 4) with less than 7 Bq 44Ti-breakthrough within 
10 min ready for following radiolabeling reactions [21, 38, 40].
2.2. Synthesis of [44Sc]Sc-PSMA-617
DOTA is used as bifunctional chelator in PSMA-617 (cf. Figure 1) requiring elevated tempera-
tures for complex formation. Commonly DOTA-based radiopharmaceuticals are prepared 
using 95°C; therefore, it was evident to choose this as radiolabeling temperature for generator 
as well as for cyclotron produced scandium-44 [21, 25].
Due to the low activity obtained from the 44Ti/44Sc-generator, evaluation of the influence of 
precursor amount and reaction time on radiochemical yield resulted in apparent molar activi-
ties of 6.50 ± 0.76 MBq/nmol [21] while values of 5–10 MBq/nmol using cyclotron produced 
scandium-44 are possible [20].
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With regard to the reported radiochemical yields of >97% [20, 21], it seems not necessary to 
evaluate a purification method. Nevertheless, removal of unwanted ions (e.g., acetate ions, 
uncomplexed 44Sc3+) from the crude product solution is of interest especially with a view to 
clinical application. The purification method of choice is solid phase extraction. This cheap 
and easy method is commonly used when it is necessary to purify radiopharmaceuticals. 
Solid phase extraction with C-18 cartridges was suitable for further purification. After equili-
bration of the cartridge, almost quantitative retention of [44Sc]Sc-PSMA-617 on the cartridge 
and product recovery with >90% efficacy is possible [21].
2.3. Preclinical evaluation
The evaluation of the logD values of the 68Ga-, 44Sc- and 177Lu-complexes and [68Ga]Ga-PSMA-11 
revealed that the values are in the same range for the PSMA-617 complexes and reduced for 
[68Ga]Ga-PSMA-11(cf. Table 4) [20].
The presence of metal cations like Fe3+ or other chelators can cause a release of the radionu-
clide from PSMA-617. As this is a crucial factor for later use as a radiopharmaceutical stability 
of [44Sc]Sc-PSMA-617 against transmetallation, transchelation as well as its stability in human 
serum and in final formulation was investigated. To determine the stability in the presence of 
relevant metal cations, those typically present in vivo (Ca2+, Fe3+, Mg2+), at levels significantly 
higher compared to normal in vivo levels, were chosen. Transchelation was determined 
against DTPA and EDTA, two chelators forming scandium complexes already at room tem-
perature. In all stability experiments more than 95% of [44Sc]Sc-PSMA-617 remained intact 
even after 24 h incubation [21]. (cf. Table 3).
Eppard et al. as well as Umbricht et al. determined the binding affinity of natSc-PSMA-617 
but by different methods and cell lines [20, 21]. Due to the differences in the experimental 
set up, the results are not directly comparable. Nevertheless, there are similarities. Binding 
affinity to the target were for [44Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 in the same range 
cf. (Table 4). Similar results could be observed for the internalization of the radioligands. 
Uptake was comparable for all compounds without any significant differences within the 
Time (h) % intact [44Sc]Sc-PSMA-617 ± SD
Ca2+ Mg2+ Fe3+ EDTA DTPA NaCl Human 
serum
0.5 98.0 ± 0.0 98.7 ± 0.5 97.3 ± 0.9 96.7 ± 0.1 96.7 ± 1.2 98.7 ± 0.5 98.7 ± 0.5
1 98.3 ± 0.5 98.3 ± 0.5 98.0 ± 0.8 97.3 ± 0.1 97.7 ± 0.5 98.0 ± 0–8 98.0 ± 0.8
2 97.0 ± 0.1 98.0 ± 0.8 98.0 ± 0.8 97.3 ± 0.1 97.0 ± 0.8 97.7 ± 1.3 98.0 ± 0.4
4 97.0 ± 1.4 97.7 ± 0.5 96.7 ± 0.5 97.3 ± 0.1 96.7 ± 0.5 97.3 ± 0.5 97.0 ± 0.8
24 96.7 ± 0.8 97.2 ± 0.8 95.0 ± 1.4 95.9 ± 1.2 95.1 ± 0.8 96.0 ± 0.8 96.3 ± 0.9
Table 3. Stability of [44Sc]Sc-PSMA-617 at 37°C in the presence of different metal cations and in the presence of DTPA and 
EDTA, at 10−2 M concentration respectively (n = 3).
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experimental set up [20, 21]. Additionally, it was possible to prove PSMA-specific uptake/
internalization for all radioligands used employing a PC-3 PIP/flu tumor model [20, 21].
Umbricht et al. performed biodistribution and small animal imaging studies in PC-3 PIP and 
PC-3 flu tumor-bearing mice directly comparing [44Sc]Sc-PSMA-617 with [177Lu]Lu-PSMA-617, 
[68Ga]Ga-PSMA-617 and [68Ga]Ga-PSMA-11 under the same in vivo conditions [20]. The study 
confirmed comparable in vitro behavior, which was expected due to similar coordination behav-
ior of scandium-44 and lutetium-177 [20, 48]. The similar chemical behavior of the two nuclides 
is also evident in vivo in the pharmacokinetics of the radiopharmaceuticals. [44Sc]Sc-PSMA-617 
and [177Lu]Lu-PSMA-617 revealed a largely identical biodistribution within in the investigated 
period of time [20]. Along with the advantage of the longer half-life of scandium-44, enabling 
late-time imaging, the increasing tumor-to-background ratio over time can be exploited [20]. 
Additional comparison with the [68Ga]Ga-PSMA-617 confirmed small differences in the phar-
macokinetics of [68Ga]Ga-PSMA-617 and [177Lu]Lu-PSMA-617 explainable with the different 
coordination chemistry of gallium and lutetium [20].
2.4. Synthesis and quality control for human use
The pharmacopeia contains recognized pharmaceutical rules on the quality, testing, storage 
and labeling of medicinal products and the substances, materials and methods used in their 
manufacture and testing. It is legally binding [21].
As scandium-44 is a new isotope for human PET application, there is no monograph in 
the European or another pharmacopeia available for the preparation of scandium-44 or 
44Sc-radiopharmaceuticals. Therefore, quality control was performed based on the mono-
graph for [68Ga]Ga-DOTATOC of the European Pharmacopeia [67].
With respect to the use of generator-derived scandium-44, special attention has to be paid to 
the quality control of the titanium-44 content in the final formulation.
To ensure the quality of [44Sc]Sc-PSMA-617, the radiolabeling procedure was modified for 
patient application. Since only a maximum of 180 MBq scandium-44 is available via the gen-
erator per elution and the time from the beginning of the generator elution to the injection 
to the patient is 3–4 h, it was necessary to guarantee high and stable radiochemical yields. 
To achieve this, the amount of precursor was increased to 38.4 nmol, and 9 vol% ethanol 
Log D Relative PSMA-binding affinity
LNCaP cells PC-3 PIP cells
[44Sc]Sc-PSMA-617 −4.21 ± 0.04 1.47 1.18
[177Lu]Lu-PSMA-617 −4.18 ± 0.06 1 1
[68Ga]Ga-PSMA-617 −4.30 ± 0.10 1.08 0.54
[68Ga]Ga-PSMA-11 −4.82 ± 0.07 0.58 0.45
Table 4. Log D (n = 3–5) and relative PSMA-binding affinity as the inverse molar ratio of the average KD values as determined in cell studies with LNCaP cells [21] and PC-3 PIP cells [20] according to Reddy et al. [66].
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was added to the radiolabeling mixture. Ethanol has two tasks: to improve radiolabeling 
efficacy [68] and to prevent radiolysis in the initial radiolabeling mixture. Its use as scav-
enger is very important to ensure radiochemical purity as radiolysis by-products can cause 
undesired and serious side effects while their removal is time-consuming and complicated. 
Additionally, C-18 purification was performed by default. This step removes potentially 
remaining 44Ti-breakthrough, uncomplexed scandium-44 as well as ammonium acetate buf-
fer prior to final formulation of the radiopharmaceutical. Although this step extends synthe-
sis time, its contribution to ensure radiochemical and especially radionuclidic purity is very 
important. With respect to the use of generator-derived scandiuim-44, the 44Ti-breakthrough 
was of major interest. During process set-up, it was even tested twice, in the radiolabeling 
mixture and final formulation. It was measured not earlier than 120 h after synthesis in a 
γ-spectrometer at 67.9 and 78.3 keV. Titanium-44 was not traceable in any of the quality 
control samples.
Due to the limited activity derived from the 44Ti/44Sc-generator system, the apparent molar 
activity was 3.05 ± 0.36 MBq/nmol at time of calibration (end of synthesis) which is consid-
erably lower compared to [68Ga]Ga-PSMA-11 (14–355 MBq/nmol) or [68Ga]Ga-DOTA-TOC 
(4–72 MBq/nmol).
Parameters checked during the quality control procedure were listed in Table 5.
Due to the nature of radiopharmaceuticals sterility, breakthrough and content of long liv-
ing radionuclides could not be determined before release of the final radiopharmaceutical. 
Therefore, only a preliminary release was possible. Final release of the respective batch was 
performed with receipt of the last test results.
Method Acceptance criteria
Volume activity Dose calibrator 5–15 MBq/ml
Visual appearance Optical Clear, colorless
Drug Identity Radio-HPLC 11.3 ± 0.4 min
Nuclide identity γ-Spectroscopy 511 ± 25 keV
Decay measurements 3.97 ± 0.2 h
pH Indicator strip 4–8.5
Apparent molar activity Calculation 0.7–8 MBq/nmol
Radiochemical purity Radio-HPLC/Radio-TLC ≥ 95%
Long living nuclides γ-Spectroscopy Yes/No
Breakthrough γ-Spectroscopy < 0.001%
Filter integrity Bubble point > 3447 mbar
Endotoxins LAL-test < 17.5 IU/ml
Sterility According Ph. Eur. Sterile
Table 5. Parameters checked during quality control with acceptance criteria and average value measured.
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Patient no. Age Weight (kg) Hematocrit Injected activity 
(MBq)
Injected activity (MBq/kg) PSA (ng/ml)
1 70 78 0.33 50.00 0.64 453.00
2 72 80 0.30 62.23 0.78 26.00
3 67 70 0.39 39.61 0.57 7.20
4 70 80 0.30 50.00 0.63 139.00
5 67 104 0.29 48.95 0.47 3000.0
Mean 69 82.4 0.32 50.16 0.62
SD 2.2 12.76 0.04 8.04 0.11
Table 6. Details of study population [21, 69, 70].
3. Part II: Dosimetry
Theranostics and personalized medicine in oncology are in need for highly sensitive and 
specific diagnostic PET probes that may be radiolabeled with therapeutic radionuclides [18]. 
It is assumed that diagnostic PET agent distribution is more appropriate for prediction of 
therapeutic dose increasing therapeutic outcome [18]. Among the several matched pairs for 
imaging and therapy used in nuclear medicine, focus is on the PET nuclides gallium-68 and 
scandium-44 as imaging counterpart for lutetium-177.
3.1. Methodology
For the first clinical application, five men with progressive mCRPC enrolled for [177Lu]Lu-PSMA-617 
therapy received [44Sc]Sc-PSMA-617 for PET imaging (cf. Table 6) [21, 69, 70].
The study protocol stipulates PET/CT imaging starting with a dynamic PET scan of abdomen 
with kidneys in the field of view (FOV) followed by a low dose CT scan and three static whole-
body scans from skull to mid-thigh acquired 45 minutes, 2 h and 19.5 h post injection with 
preceding low-dose CT. Quantitative analysis was performed visually to identify organs of 
increased tracer uptake as source organs for further dosimetric calculations. Residence times, 
organ-absorbed doses (mSv/MBq) as well as effective doses were calculated during quanti-
tative analysis [21, 69, 70] and the maximum permissible activity as well as the maximum 
number of therapy cycles (6 GBq per cycle) which can be administered were determined [70].
3.2. First in-human studies
Following the promising preclinical results, Eppard et al. conducted a first-in-human application 
[21, 69, 70].
In all patients, PSMA-positive metastases were detectable by [44Sc]Sc-PSMA-617 PET/
CT applying a single dose of 50.45 ± 9.25 MBq. Visual comparison with images from pre-
vious [68Ga]Ga-PSMA-11-PET/CT those from [44Sc]Sc-PSMA-617 PET/CT were found to 
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be at least equal at a significantly reduced dose. Direct comparison of [68Ga]Ga-PSMA-11 
and [44Sc]Sc-PSMA-617 PET/CT images as well as planar scintigraphy and SPECT/CT of 
[177Lu]Lu-PSMA-617 in one patient is depicted in Figure 2.
Due to the longer half-life of scandium-44, patient management could become more flexible 
through its use allowing PET/CT imaging several hours post injection (Figure 3) [20]. Indeed 
using low doses still and late time point imaging still enables detection of lesions while accumu-
lated activity in urinary tract or kidney is no longer observed [21]. Qualitative detection of PSMA-
positive lesions is feasible due to increased tumor-to-background ratios and resulting improved 
image contrast [21].
Khawar et al. reported estimated residence times (MBq-h/MBq) to be prolonged in the 
liver followed by the kidneys, urinary bladder, bone marrow and rest of organs compared 
with [68Ga]Ga-PSMA-617 [69]. Also, the study revealed that kidneys (3.19E-01 mSv/MBq; 
Figure 2. Maximal intensity projection (top) and representative slice (bottom) of PET/CT examination of a 70-year-old 
patient suffering of mCRPC with high tumor load using (A) [44Sc]Sc-PSMA-617 (50 MBq, 60 min p.i.), and (B) [68Ga]
Ga-PSMA-11 (120 MBq, 60 min p.i.). (C) On the right-hand side, the planar scintigraphy (top) and a representative slice 
of the post-therapy SPECT/CT scan, about 24 h after application of 6.7 GBq of [177Lu]Lu-PSMA-617 are shown [21].
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Figure 3. PET/CT whole body images at different time points p.i. using [44Sc]Sc-PSMA-617: (A) 30 min, (B) 120 min, and 
(C) 19 h [21].
range: 1.78 E-01-4.88E-01 mSv/MBq) are the critical organs at risk receiving the high-
est dose followed by the urinary bladder wall, spleen, salivary glands, liver and small 
intestine while bone marrow dose was less and consequently not included in organs at 
risk for therapeutic application [69]. These findings are consistent with the results for 
small PSMA ligands of previous studies [71, 72]. Overall, the study confirmed absorbed 
doses to be higher for [44Sc]Sc-PSMA-617 than for [68Ga]Ga-PSMA-617, [68Ga]Ga-PSMA-11, 
[68Ga]Ga-PSMA-I&T but less than [124I]I-PSMA [69]. Also the mean effective dose was 
found to be higher than [68Ga]Ga-PSMA-617, [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA-I&T but 
less than [124I]I-PSMA [69, 72].
In a follow-up study, Khawar et al. used [44Sc]Sc-PSMA-617 PET/CT for pre-therapeutic 
dosimetry estimating the organ doses of [177Lu]Lu-PSMA-617 administered [70]. This was 
performed by mathematical exploration of pharmacokinetics of [44Sc]Sc-PSMA-617 to that 
of [177Lu]Lu-PSMA-617. As preclinical in vitro and in vivo studies proofed better correlation 
between [44Sc]Sc-PSMA-617 and [177Lu]Lu-PSMA-617 as compared to 68Ga-PSMA agents, the 
authors assumed that dosimetric analysis from 19.5 h imaging data of [44Sc]Sc-PSMA-617 
could be converted into 6.7 d imaging data for [177Lu]Lu-PSMA-617 [20, 70]. Total activity 
(MBq) in source organs and whole body from reconstructed images of dynamic data, and 
three static whole body PET/CT images were decay corrected back to time of injection using 
scandium-44 half-life and then forward decay corrected using half-life of lutetium-177 for 
calculation [70].
Table 7 shows the mean residence times (MBq-h/MBq) for [44Sc]Sc-PSMA-617 and based on 
[44Sc]Sc-PSMA-617 pharmacokinetics for [177Lu]Lu-PSMA-617 [69, 70].
Also for [177Lu]Lu-PSMA-617, kidneys appeared to be the organ at risk (mean absorbed dose 
0.44 mSv/MBq) followed by the salivary glands, liver, small intestine, spleen and urinary 
bladder wall [70]. The mean bone marrow absorbed dose was reported to be 0.05 mSv/MBq, 
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and the mean whole body dose was 0.08 mSv/MBq [70]. These findings are comparable with 
literature [11, 13, 17, 19]. Total dose (Gy) per cycle administered lies in a range from 2 till 
3.26 Gy although applying the same therapeutic activities [70]. Due to the use of 3D instead 
of usual 2 D dosimetric analysis, it was found that it is possible to administer a mean dose of 
52 Gy to reach a dose limit of 23 Gy [70] which is significantly higher than reported before 
with 30 Gy [13].
All together both studies proved that dosimetry using [44Sc]Sc-PSMA-617 PET/CT is possible 
applying a protocol which could be implemented in clinical daily routine.
4. Conclusion
Recent studies demonstrated the high potential of [44Sc]Sc-PSMA-617 for PET imaging in 
a preclinical as well as a clinical setting where it revealed more similar characteristics to 
[177Lu]Lu-PSMA-617 than the routinely used [68Ga]Ga-PSMA-11 [20, 21].
While images at early time points are comparable with those of [68Ga]Ga-PSMA-11, the advan-
tages of scandium-44 over gallium-68 show up at late time points due to its longer half-life. 
Enabling delayed image acquisition would simplify patient management at improved image 
quality and allows improved pre-therapeutic dosimetry for therapy with [177Lu]Lu-PSMA-617. 
Especially for pre-therapeutic dosimetry scandium-44 would be beneficial as implementation 
in the clinical setting is uncomplicated, and there is no need for patient hospitalization. Together 
with the possibility transporting scandium-44 and 44Sc-radiopharmaceuticals further routes to 
radiopharmaceutical institutions without option for in-house production scandium-44 could 
make a significant contribution to patient care even in remote areas.
PT No [44Sc]Sc-PSMA-617 [177Lu]Lu-PSMA-617
Mean± SD Mean± SD
Organs
Salivary glands 0.03± 0.027 0.24 0.21
Kidneys 0.24± 0.109 1.51 0.48
Liver 0.35± 0.263 4.46 1.72
Spleen 0.07± 0.031 0.18 0.07
Small Intestine 0.05± 0.029 0.63 0.37
Bone marrow 0.09± 0.047 0.52 0.69
Urinary bladder contents 0.18± 0.195 0.33 0.32
Remainder of body 1.82 0.684 46.58 16.04
Table 7. Mean residence times (MBq-h/MBq) for [44Sc]Sc-PSMA-617 and estimated for [177Lu]Lu-PSMA-617 on basis of 
[44Sc]Sc-PSMA-617 pharmacokinetics [69, 70].
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